Cargando…
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to t...
Autores principales: | Ishii, Taisuke, Tanaka, Tetsuhiro, Nangaku, Masaomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898206/ https://www.ncbi.nlm.nih.gov/pubmed/33628028 http://dx.doi.org/10.2147/TCRM.S293879 |
Ejemplares similares
-
Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022) -
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
por: Becker, Kimberly A., et al.
Publicado: (2017) -
Recent advances in understanding of chronic kidney disease
por: Yamaguchi, Junna, et al.
Publicado: (2015) -
Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease
por: Hirakawa, Yosuke, et al.
Publicado: (2017) -
Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)